Although @entity28 is a global epidemic, the physiological mechanisms involved are not well understood. Recent advances reveal that susceptibility to @entity28 can be programmed by maternal and neonatal nutrition. Specifically, a maternal low-protein diet during pregnancy causes decreased intrauterine growth, rapid postnatal catch-up growth and an increased risk for diet-induced @entity28 . Given that the synthesis of the neurotransmitter @entity750 ( @entity750 ) is nutritionally regulated and @entity750 is a trophic factor, we hypothesised that maternal diet influences fetal @entity750 exposure, which then influences development of the central appetite network and the subsequent efficacy of @entity750 to control energy balance in later life. Consistent with our hypothesis, pregnant @entity35 fed a low-protein diet exhibited elevated serum levels of @entity750 , which was also evident in the placenta and fetal brains at embryonic day 16.5. This increase was associated with reduced levels of 5-HT2CR, the primary @entity750 receptor influencing appetite, in the fetal, neonatal and adult hypothalamus. As expected, a reduction of 5-HT2CR was associated with impaired sensitivity to @entity750 -mediated appetite suppression in adulthood. @entity750 primarily achieves effects on appetite by 5-HT2CR stimulation of @entity9210 ( @entity9210 ) peptides within the @entity2339 ( @entity16888 ). We show that 5-HT2ARs are also anatomically positioned to influence the activity of @entity16888 @entity9210 neurons and that mRNA encoding 5-HT2AR is increased in the hypothalamus ofin uterogrowth-restricted offspring that underwent rapid postnatal catch-up growth. Furthermore, these animals at 3  months of age are more sensitive to appetite suppression induced by 5-HT2AR agonists. These findings not only reveal a @entity750 -mediated mechanism underlying the programming of susceptibility to @entity28 , but also provide a promising means to correct it, by treatment with a 5-HT2AR agonist.

5-HT2A and 5-HT2C receptors as hypothalamic targets of developmental programming in male XXXX .

@entity9210 :: ('24664(Tax:10116)', 'Gene') :: ['pro-opiomelanocortin', 'POMC'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity'] @entity16888 :: ('MESH:D000386', 'Disease') :: ['ARC'] @entity2339 :: ('MESH:D007029', 'Disease') :: ['arcuate nucleus of the hypothalamus'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['5-hydroxytryptamine', '5-HT'] @entity35 :: ('10116', 'Species') :: ['rats']
@entity35 :: (10116,Species) :: ['rats']
